Tế bào trung mô từ tủy xương người biểu hiện S-TRAIL như một phương tiện vận chuyển tế bào trong liệu pháp điều trị glioma ở người

Louis, 2007, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol, 114, 97, 10.1007/s00401-007-0243-4

Jemal, 2003, Cancer statistics, 2003, CA Cancer J Clin, 53, 5, 10.3322/canjclin.53.1.5

Maher, 2001, Malignant glioma: Genetics and biology of a grave matter, Genes Dev, 15, 1311, 10.1101/gad.891601

Aboody, 2000, Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas, Proc Natl Acad Sci U S A, 97, 12846, 10.1073/pnas.97.23.12846

Kim, 2006, Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression, Clin Cancer Res, 12, 5550, 10.1158/1078-0432.CCR-05-2508

Shimato, 2007, Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma, Gene Ther, 14, 1132, 10.1038/sj.gt.3302932

Benedetti, 2000, Gene therapy of experimental brain tumors using neural progenitor cells, Nat Med, 6, 447, 10.1038/74710

Ehtesham, 2002, The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma, Cancer Res, 62, 5657

Kim, 2005, PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model, Clin Cancer Res, 11, 5965, 10.1158/1078-0432.CCR-05-0371

Danks, 2007, Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma, Cancer Res, 67, 22, 10.1158/0008-5472.CAN-06-3607

Ehtesham, 2002, Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand, Cancer Res, 62, 7170

Shah, 2005, Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression, Ann Neurol, 57, 34, 10.1002/ana.20306

Brooke, 2007, Therapeutic applications of mesenchymal stromal cells, Semin Cell Dev Biol, 18, 846, 10.1016/j.semcdb.2007.09.012

Chamberlain, 2007, Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing, Stem Cells, 25, 2739, 10.1634/stemcells.2007-0197

Kopen, 1999, Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains, Proc Natl Acad Sci U S A, 96, 10711, 10.1073/pnas.96.19.10711

Orlic, 2001, Mobilized bone marrow cells repair the infarcted heart, improving function and survival, Proc Natl Acad Sci U S A, 98, 10344, 10.1073/pnas.181177898

Hofstetter, 2002, Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery, Proc Natl Acad Sci U S A, 99, 2199, 10.1073/pnas.042678299

Mahmood, 2003, Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells, Neurosurgery, 53, 697, 10.1227/01.NEU.0000079333.61863.AA

Spaeth, 2008, Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells, Gene Ther, 15, 730, 10.1038/gt.2008.39

Studeny, 2004, Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents, J Natl Cancer Inst, 96, 1593, 10.1093/jnci/djh299

Studeny, 2002, Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors, Cancer Res, 62, 3603

Nakamizo, 2005, Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas, Cancer Res, 65, 3307, 10.1158/0008-5472.CAN-04-1874

Stagg, 2004, Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy, Hum Gene Ther, 15, 597, 10.1089/104303404323142042

Nakamura, 2004, Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model, Gene Ther, 11, 1155, 10.1038/sj.gt.3302276

Stoff-Khalili, 2007, Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma, Breast Cancer Res Treat, 105, 157, 10.1007/s10549-006-9449-8

Sonabend, 2008, Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma, Stem Cells, 26, 831, 10.1634/stemcells.2007-0758

Wiley, 1995, Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity, 3, 673, 10.1016/1074-7613(95)90057-8

Pitti, 1996, Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family, J Biol Chem, 271, 12687, 10.1074/jbc.271.22.12687

Almasan, 2003, Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy, Cytokine Growth Factor Rev, 14, 337, 10.1016/S1359-6101(03)00029-7

Kagawa, 2001, Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene, Cancer Res, 61, 3330

Kasuga, 2004, Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitors, Cancer Sci, 95, 840, 10.1111/j.1349-7006.2004.tb02191.x

Roth, 1999, Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity, Biochem Biophys Res Commun, 265, 479, 10.1006/bbrc.1999.1693

Pollack, 2001, Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells, Clin Cancer Res, 7, 1362

Rieger, 1998, APO2 ligand: A novel lethal weapon against malignant glioma?, FEBS Lett, 427, 124, 10.1016/S0014-5793(98)00409-8

Ashkenazi, 1999, Safety and antitumor activity of recombinant soluble Apo2 ligand, J Clin Invest, 104, 155, 10.1172/JCI6926

Walczak, 1999, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat Med, 5, 157, 10.1038/5517

Naka, 2002, Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice, Cancer Res, 62, 5800

Chinnaiyan, 2000, Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy, Proc Natl Acad Sci U S A, 97, 1754, 10.1073/pnas.030545097

Ray, 2003, Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11, Cancer Res, 63, 4713

Fulda, 2002, Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo, Nat Med, 8, 808, 10.1038/nm735

Yagita, 2004, TRAIL and its receptors as targets for cancer therapy, Cancer Sci, 95, 777, 10.1111/j.1349-7006.2004.tb02181.x

Takeda, 2007, Targeting death-inducing receptors in cancer therapy, Oncogene, 26, 3745, 10.1038/sj.onc.1210374

Mohr, 2008, Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model, J Cell Mol Med, 12, 2628, 10.1111/j.1582-4934.2008.00317.x

Kim, 2008, Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma, Cancer Res, 68, 9614, 10.1158/0008-5472.CAN-08-0451

Shah, 2004, Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy, Cancer Res, 64, 3236, 10.1158/0008-5472.CAN-03-3516

Shah, 2005, In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis, Mol Ther, 11, 926, 10.1016/j.ymthe.2005.01.017

Menon, 2007, Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells, Stem Cells, 25, 520, 10.1634/stemcells.2006-0257

Schmidt, 2004, Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas, J Neurooncol, 68, 207, 10.1023/B:NEON.0000033364.43142.bf

Secchiero, 2009, Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells, Stem Cells, 26, 2955, 10.1634/stemcells.2008-0512

Shah, 2003, Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo, Oncogene, 22, 6865, 10.1038/sj.onc.1206748

Lee, 2002, Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector, Neoplasia, 4, 312, 10.1038/sj.neo.7900245

Candolfi, 2007, Intracranial glioblastoma models in preclinical neuro-oncology: Neuropathological characterization and tumor progression, J Neurooncol, 85, 133, 10.1007/s11060-007-9400-9

Birnbaum, 2007, Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines, J Neurooncol, 83, 241, 10.1007/s11060-007-9332-4

Nagane, 2000, Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo, Cancer Res, 60, 847

Lacour, 2001, Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis, Cancer Res, 61, 1645

Saito, 2004, Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model, Cancer Res, 64, 6858, 10.1158/0008-5472.CAN-04-1683

Newlands, 1997, Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials, Cancer Treat Rev, 23, 35, 10.1016/S0305-7372(97)90019-0

Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330

Uzzaman, 2007, Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells, J Neurosurg, 106, 646, 10.3171/jns.2007.106.4.646

Hingtgen, 2008, Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and temozolomide, Mol Cancer Ther, 7, 3575, 10.1158/1535-7163.MCT-08-0640